Cargando…
Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets
Nanocrystallization and amorphization have proven to be two effective strategies to improve the bioavailability of water-insoluble drugs. The purpose of our work was to develop a nano-formulated tablet of sirolimus (SRL) for enhanced dissolution. Amorphous SRL nanocomposites were prepared using anti...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161202/ https://www.ncbi.nlm.nih.gov/pubmed/30208637 http://dx.doi.org/10.3390/pharmaceutics10030155 |
_version_ | 1783358939460534272 |
---|---|
author | Shen, Yudong Li, Xingya Le, Yuan |
author_facet | Shen, Yudong Li, Xingya Le, Yuan |
author_sort | Shen, Yudong |
collection | PubMed |
description | Nanocrystallization and amorphization have proven to be two effective strategies to improve the bioavailability of water-insoluble drugs. The purpose of our work was to develop a nano-formulated tablet of sirolimus (SRL) for enhanced dissolution. Amorphous SRL nanocomposites were prepared using anti-solvent precipitation via a high-gravity rotating packed bed. Various factors that affect particle size and size distribution, such as excipients, rotating speed, antisolvent/solvent flow rate, were investigated. Structure, stability and in vitro dissolution of the as-prepared SRL were evaluated. Furthermore, the nanoparticulated SRL tablet formula was screened to control drug release. Importantly, SRL tablets exhibit different dissolution profile by adjusting HPMC (hydroxypropyl methyl cellulose) content, which makes them more suitable for various formulation developments. |
format | Online Article Text |
id | pubmed-6161202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61612022018-10-01 Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets Shen, Yudong Li, Xingya Le, Yuan Pharmaceutics Article Nanocrystallization and amorphization have proven to be two effective strategies to improve the bioavailability of water-insoluble drugs. The purpose of our work was to develop a nano-formulated tablet of sirolimus (SRL) for enhanced dissolution. Amorphous SRL nanocomposites were prepared using anti-solvent precipitation via a high-gravity rotating packed bed. Various factors that affect particle size and size distribution, such as excipients, rotating speed, antisolvent/solvent flow rate, were investigated. Structure, stability and in vitro dissolution of the as-prepared SRL were evaluated. Furthermore, the nanoparticulated SRL tablet formula was screened to control drug release. Importantly, SRL tablets exhibit different dissolution profile by adjusting HPMC (hydroxypropyl methyl cellulose) content, which makes them more suitable for various formulation developments. MDPI 2018-09-11 /pmc/articles/PMC6161202/ /pubmed/30208637 http://dx.doi.org/10.3390/pharmaceutics10030155 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shen, Yudong Li, Xingya Le, Yuan Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets |
title | Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets |
title_full | Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets |
title_fullStr | Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets |
title_full_unstemmed | Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets |
title_short | Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets |
title_sort | amorphous nanoparticulate formulation of sirolimus and its tablets |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161202/ https://www.ncbi.nlm.nih.gov/pubmed/30208637 http://dx.doi.org/10.3390/pharmaceutics10030155 |
work_keys_str_mv | AT shenyudong amorphousnanoparticulateformulationofsirolimusanditstablets AT lixingya amorphousnanoparticulateformulationofsirolimusanditstablets AT leyuan amorphousnanoparticulateformulationofsirolimusanditstablets |